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ASCITES BY MEASURING GALLBLADDER WALL THICKNESS” 
 
ABSTRACT: 
 
BACKGROUND: 
The conventional diagnostic method for most of the causes of ascites is diagnostic 
tapping of the ascitic fluid (paracentesis). This method is an invasive method. It is 
also a time consuming method.Ultrasonography has positive predictive value of 
93-95% in determination of gallbladder wall thickness if the thickness is 1 mm. It 
is nearly 100% sensitive when the thickness is > 1.5 mm. 
AIMS: 
In our study we aim to find out the diagnostic value of ultrasonographic 
measurement of gallbladder wall thickness in differentiation of cirrhotic ascites 
from peritoneal carcinomatosis induced ascites. We also study the relationship 
between serum albumin levels and gallbladder wall thickness 
PATIENTS AND METHODS: 
We have included 60 patients in our study. Patients admitted with chronic liver 
disease with ascites, malignant induced ascites at medical wards, Institute of 
Internal medicine.Patients are subjected to routine blood investigations like 
complete blood count,renal function tests, liver function tests, PT-INR.Patients 
Gallbladder wall thickness will be assessed by Ultrasonography after 8 hours of 
fasting with fill gallbladder. Three measurements of gallbladder wall thickness 
were taken at each site and average measurement was used for analysis. A single 
operator performed all the ultrasound examinations both in cirrhotic patients and 
peritoneal carcinomatosis patients. Real time bidimensional and Doppler 
ultrasound examinations were performed by using 3.5 MHz transducer. Thickness 
more than 3 mm was considered significant. 
CONCLUSION: 
According to our study,  thesonographic study of the gallbladder will be helpful as 
a simple and initial screening tool in differentiating between cirrhosis induced and 
peritoneal carcinomatosis induced ascites. 
Hypoalbuminemia is correlated well with the development of thickened 
gallbladder in cirrhosis induced ascites. 
 
 
KEYWORDS: 
Gallbladder wall thickness, Serum Albumin, Prothrombin time, International 
normalized ratio,Ultrasonogram. 
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INTRODUCTION 
 
Ascites is the term derived from greek word ‘askos’ which  means ‘bag 
like’. Ascites denotes when there is pathological accumulation of fluid inside the 
peritoneal cavity. There are multiple causes of ascites.  Alcoholic liver disease is 
the commenest of cirrhosis  worldwide  which is contributing to about 80-85 % of 
the cases. Another devastating cause of ascites is peritoneal carcinomatosis 
induced ascites. 
  Malignant ascites is an important sign of peritoneal carcinomatosis. The 
common etiologies for malignant induced ascites are gastric malignancy, ovary, 
colorectum, lung, breast, pancreas, uterus, lymphoma. Malignant ascites accounts 
for 10% of the causes of ascites. The presence of ascites is a worst prognostic sign 
in peritoneal carcinomatosis. The average life expectancy is approximately 20-24 
weeks after the diagnosis of malignant ascites(3) in a patient. 
The early diagnosis of peritoneal carcinomatosis induced ascites is very 
important in the diagnosis and management of primary malignancy. 
The conventional diagnostic method for most of the causes of ascites is 
diagnostic tapping of the ascitic fluid (paracentesis). This method is an invasive 
method. It is also a time consuming method. 
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 Ultrasonography has positive predictive value of 93-95% in determination 
of gallbladder wall thickness if the thickness is 1 mm. It is nearly 100% sensitive 
when the thickness is > 1.5 mm. The normal gallbladder will be appearing  as a 
pencil thin line on ultrasonogram which is echogenic (4). 
 Several studies have reported that gallbladder wall is getting thickened in 
cirrhosis induced ascites. . Hypoalbuminemia causes edema and structural changes 
in the gallbladder wall.  It leads to gallbladder wall  thickening. It  also affects the 
gallbladder contractility(1). So the mechanisms which are responsible for 
gallbladder wall thickening might  occur earlier in the pathogenesis of cirrhosis. 
Hypoalbuminemia precedes the onset of portal hypertension.  
In our study we aim to find out the diagnostic value of ultrasonographic 
measurement of gallbladder wall thickness in differentiation ofcirrhotic ascites 
from peritoneal carcinomatosis induced ascites. We also study the relationship 
between serum albumin levels and gallbladder wall thickness. 
 
 
 
 
 
 
 
  
 
 
AIM AND OBJECTIVE 
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AIMS AND OBJECTIVES 
 
 
 
 
• To study the usefulness of measuring gallbladder wall thickness in the 
Differentiation of  cirrhotic ascites from malignant induced ascites. 
 
• To study the correlation between serum albumin levels and gallbladder wall 
thickness.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
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REVIEW OF LITERATURE 
 
Ascites is the term derived from greek word ‘askos’ which means ‘bag like’. 
Ascites denotes when there is pathological accumulation of fluid inside the 
peritoneal cavity. The peritoneum is a serous membrane that forms the inner lining 
of the abdominal cavity. It is composed of a layer of mesothelium which is 
supported by a thin layer of connective tissue. 
 
 There are two layers of peritoneum. The outer layer is parietal peritoneum 
which lines the abdominal cavity. The inner layer is visceral peritoneum which 
lines the internal organs. The potential space between these two layers is called as  
peritoneal cavity. It is filled with a small amount of serous fluid( approximately 
30-50 ml ). Mild ascites will be  difficult to appreciate clinically.  
 
But moderate to severe ascites will produce abdominal distension. Most 
experts recommend a diagnostic tapping of the ascitic fluid(diagnostic paracentesis 
) should be performed to know about the etiology of ascites. The fluid is then 
analysed for gross appearance of the ascitic fluid and its protein level, albumin, cell 
count, microbiological culture, gram stain, cytology. 
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The Serum Ascites- Albumin Gradient ( SAAG ) is most useful in  
determining the etiology  of ascites. A high SAAG (>1.1 g/dl) indicates the ascites 
is due to portal hypertension. A high SAAG ascites is further classified depending 
upon the ascitic fluid protein concentration. When the SAAG is less than 1.1 g/dl , 
it is called as low SAAG ascites. 
 
Fig : Algorithm for the diagnosis of ascites according to the serum-ascites 
albumin gradient (SAAG). IVC, inferior vena cava. 
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The commonest cause of ascites around the world  is cirrhosis. It  accounts 
for 80-84% of the cases of ascites. Congestive cardiac failure, peritoneal 
carcinomatosis and mixed ascites resulting from cirrhosis and a second disease 
account for 10-15% cases(2). Less common causes includes infection, massive 
hepatic metastasis, pancreatitis and renal failure. The ascites can also be classified 
as either exudative or transudative. There are some diseases which can cause both 
exudative or transudative ascites. This diseases includes tuberculous peritonitis, 
purulent peritonitis, congestive cardiac failure, pancreatitits, peritoneal 
carcinomatosis. 
 
The pathogenesis of ascites is complex. The most recent theory among the 
postulations is peripheral arterial vasodilatation hypothesis. It has conveyed that 
both older overfill and underfill theories are correct. But  each theory  is  operative 
at a different levels of ascites formation.Ascites in patients with cirrhosis is the 
result of portal hypertension followed by renal salt and water retention. Portal 
hypertension signifies elevation of the pressure within the portal venous system. 
According to Ohm's law, pressure is the product of resistance and flow. Increased 
hepatic resistance occurs by several mechanisms.  
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At  first, there is  development of hepatic fibrosis, which defines cirrhosis, 
disrupts the normal architecture of the hepatic sinusoids and impedes normal blood 
flow through the liver. Second,there is  activation of hepatic stellate cells, which 
mediate fibrogenesis, leads to smooth muscle contraction and fibrosis. Finally, 
cirrhosis is associated with a decrease in endothelial nitric oxide synthetase 
(eNOS) production in  the liver, which results in decreased nitric oxide production 
and increased intrahepatic vasoconstriction(7). 
 
The development of cirrhosis is also associated with increased systemic 
circulating levels of nitric oxide (contrary to the decrease seen intrahepatically) as 
well as increased levels of vascular endothelial growth factor and tumor necrosis 
factor that result in splanchnic arterial vasodilatation(5). Vasodilatation of the 
splanchnic circulation results in pooling of blood and a decrease in the effective 
circulating volume, which is perceived by the kidneys as hypovolemia. 
 
As already stated above,The first abnormality that eventually leads to fluid 
retention is peripheral arterial vasodilatation and it is mediated by nitric oxide. It 
leads to intravascular hypervolemia which leads to suppression of Renin-
Angiotensin-Aldosterone system and vasopressin , norepinephrine concentration. 
As the state of vasodilatation worsens , there will be reduction in renal blood 
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supply and then renal function deteriorates. Then plasma levels of vasoconstrictor 
increases, RAAS is activated and sodium , water retention occurs. This stage is 
called as decompensated stage. Hepato-renal syndrome development is an extreme 
form of this condition(6). 
 
Cirrhosis represents an advanced stage of fibrosis and characterized by 
distortion of hepatic parenchymal anatomy and formation of regenerative nodules 
and fibrotic bands. The pathogenesis of fibro genesis is activation of stellate cell 
which is the cardinal feature of hepatic fibrosis. The stellate cells lies within the 
space of disse which is in direct contact with the hepatocytes, inflammatory 
cellthey store vitamin A in normal liver, about 40- 70% of body retinoid is stored 
in stellate cell. 
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Fig : The pathogenesis of ascites development in cirrhosis. 
  Intrahepatic portal hypertension plays a necessary role in the formation of 
ascites. Patients with presinusoidal hypertension do not develop ascites commonly. 
Due to the large hydrostatic pressure gradient in the liver leads to loss of 
intravascular volume into the sinusoidal space of disse. This fluid from the space, 
then weep out  into the abdominal cavity, as extravasated lymph. Then the 
underfilling theory takes over in the propogation of ascites. The sequestration of 
fluid in the abdomen leads to decreased effective circulatory volume and triggers 
the release of anti diuretic hormone, renin, aldosterone, further stimulation of 
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sympathetic system. This all leads to further aggravation of sodium and water 
retention. This cycle becomes vicious which increases the fluid collection in the 
peritoneal cavity.Chronic liver disease and cirrhosis is becoming very 
common(12), and its burden is increasing worldwide. Up to forty percentages of 
patients with cirrhosis were asymptomatic until the occurrence of decompensation 
in the form of  variceal bleed, hepatic encephalopathy, and SBP (spontaneous 
bacterial peritonitis ). Previously fibrosis and cirrhosis was thought to irreversible 
.But recent studies are  showing that fibrosis might be reversible in some but not 
all patients with chronic hepatitis B, hemochromatosis. 
Scar formation is mediated through increased proliferation of hepatic stellate 
cells, chemo taxis, fibro genesis, altered degradation of collagen matrix and 
interaction between hepatic stellate cells and immune system and secretion of 
inflammatory mediators. The extracellular matrix during fibro genesis consists of 
collagen and glycoproteins and hyaluronic acid. TGF beta 1 is the central molecule 
in mediating fibro genesis and TIMP-1 plays a huge role in initiation , progression 
and regression of fibro genesis. The importance of TIMP-1 can be understood from 
the fact that overexpression of human TIMP-1 in mice increased CCL4 induced 
fibrosis by seven fold. 
The three features which define cirrhosis pathologically are, 
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1. Presence of bridging fibrosis / fibrotic bands. 
2. Micro architectural distortion. 
3. Regenerative macro/ micro nodules. 
Fatty liver is the first response to many hepato toxic stimuli including 
alcohol. The initial accumulation of fat in the perivenular hepatocytes , is 
due to localisation of the enzyme alcohol dehydrogenase in that region. 
Continuous ingestion of alcohol leads to diffuse hepatic steatosis. The 
transition between steatosis and alcoholic hepatitis is less clear. Alcoholic 
hepatitis is characterised by spotty necrosis, ballooning degeneration of 
hepatocytes and infiltration of polymorphonuclear cells.  Mallory bodies are 
often present though they are not specific for alcoholic hepatitis. They are 
eosinophilic intracytoplasmic inclusions of intermediate filaments like 
keratin. Both hepatic steatosis and alcoholic hepatitis are reversible after 
alcohol abstinence. cirrhosis is present in upto 50% of the patients with 
alcoholic hepatitis and its regression is uncertain(9). 
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ETIOLOGY AND RISK FACTORS: 
Alcoholic liver disease is the most common cause of cirrhosis  worldwide 
contributing to about 80-85 % of the cases. 
NAFLD AND NASH (Nonalcoholic fatty liver disease and nonalcoholic 
steatohepatitits): around 2-3% of those with NAFLD will progress to NASH of 
which about 10% will progress to cirrhosis. 
RISKFACTORS: 
1.Heavy alcohol consumption- in males 40-80 g/day produces hepatic           
steatosis. > 160 g/day  for 10-20 yrs produces hepatitis or cirrhosis. 
Only 10-20%  of alcoholics will develop alcoholic hepatitis(10). 
    2. Health care professionals. 
    3. Obesity 
    4. Tattooing 
    5. Unprotected sexual intercourse 
    6 .Toxic and chemical exposures 
    7. Certain medications like methotrexate, sodium valproate etc. 
     8. IV drug abusers sharing intravenous needles 
     9. Blood transfusion. 
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ETIOLOGY: 
1.Alcoholic liver disease- most common cause.  
2. Viral: 
 Chronic hepatitis B. 
 Chronic hepatitis C. 
 Cytomegalovirus. 
 Epstein barr virus. 
3.Metabolic:  
 NAFLD/NASH. 
 Hemochromatosis. 
 Wilson’s disease . 
 Alpha 1 anti-trypsin deficiency. 
 Cystic fibrosis. 
 Tyrosinosis. 
 Hereditary fructose intolerance. 
 Glycogen storage diseases. 
4. Drug induced:  
 Amiodarone . 
 Methotrexate . 
 Nitrofurantoin. 
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 Anti tuberculous drugs (Isoniazid, rifampicin, pyrazinamide ) 
 Anti convulsants (Sodium valproate, phenytoin, phenobarbitone,            
carbamazepine) 
 Minocycline. 
 Trovafloxacin. 
 Halothane. 
 Amitriptyline. 
     4.Biliary cirrhosis 
Primary biliary cirrhosis. 
Primary sclerosing cholangitis . 
Autoimmune cholangiopathy. 
5. Cardiac: 
Right heart failure ( CCF ). 
Tricuspid Regurgitation. 
6. Cryptogenic 
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CLINICAL FEATURES: 
Patient with cirrhosis may be identified in the following ways : 
1. Patients may be identified on routine clinical examination. 
2. They might have undergone laboratory/radiological imaging or some 
procedures which incidentally found out the presence of chronic liver disease. 
3. They may present in a decompensated state. 
4. Some patients may never come to clinical attention. 
HISTORY: 
This  should  include  questions  to  identify  risk  factors  for  chronic  
liver disease like history of alcohol intake ,the dose, duration, calculation of 
alcohol intake in grams per day  , jaundice, diabetes,tattooing, illicit drug use, 
blood transfusion, any surgery, family history of liver diseases and autoimmune 
conditions. 
Questioning should also include those related to symptoms of chronic 
liver disease like fatigue, pedal edema, weight loss, confusion,hematemesis, 
malena, bleeding diathesis like epistaxis, ecchymotic spots, hematuria, bleeding 
gums, decreased urine output, fever, abdominal pain, altered sleep pattern. 
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Symptoms may vary from asymptomatic to overt features of 
decompensation. Patients with chronic liver disease  may have generalised 
muscle wasting, large ascites and overt hepatic encephalopathy but only mild 
jaundice. Patients with  primary biliary cirrhosis develops deep icterus but no 
muscle wasting. Patients may experience fatigue, anorexia, weight loss. 
Cutaneous manifestations may include jaundice, spider naevi, paper money skin, 
palmar erythema, dupuytrens contracture, white nails, disappearance of lunulae, 
terry nails, and finger clubbing. 
Increased peripheral aromatisation that is conversion of androgens to 
estrogen occurs in adipose tissue, skeletal muscle and decreased  metabolism of 
estrogens contributes to hyperestrogenemia  which may be responsible for loss 
of axillary and pubic hair, gynaecomastia, impotence.  
Anemia may be due to multiple causes like blood loss, folate deficiency, 
hemolysis, and hypersplenism. A unique form of hemolytic anemia can occur in 
severe alcoholic hepatitits called as Zieve’s syndrome(13). Thrombocytopenia is 
usually the first sign of portal hypertension and  hypersplenism.   
Coagulopathy  results  from  decreased  production  of coagulation factors 
and diminished absorption of  Vitamin K from the gastrointestinal tract as the 
absorption of all the nutrients will be impaired due to gastro intestinal 
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congestion. Among   the coagulation factors factor VII  will be depleted first as 
it has the shortest halflife ( 6 hours ).       
 
SYMPTOMS: 
 Fatigue. 
 weakness . 
 Poor appetite . 
 Muscle wasting. 
 Jaundice 
 Breast enlargement in men 
 Ascites 
 Parotid gland enlargement. 
 Altered sleep pattern. 
 Somnolence. 
 Pruritus. 
 Blood vomiting . 
 Redness of palms .  
 Impotence,  
 loss of libido. 
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SIGNS : 
Signs may be classified according to the Etiology and those associated 
with decompensation. 
 
SIGNS ASSOCIATED WITH ETIOLOGY: 
Alcohol related: 
o Parotid enlargement 
o Gynecomastia  
o Dupuytren’s contracture  
o Peripheral neuropathy 
o Cerebellar signs  
o Testicular atrophy- alcohol has a direct toxic effect over testis. 
Wilson’s disease: 
• Kayer Fleischer ring-  due to copper deposition in the descemet’s 
membrane of the cornea. 
• Hepatomegaly 
• Dystonia, incoordination, tremors, dysarthria, involuntary 
movements 
19 
 
 
Hemochromatosis: 
 Slate grey pigmentation of skin. 
 Testicular atrophy. 
 Diabetes mellitus. 
 Congestive cardiac failure. 
 Hepatomegaly. 
 NASH: 
 Xanthomas, xanthelesma 
 Corneal arcus 
Viral hepatitis: 
 Tattoo marks, injection marks 
Right heart failure:  
 Peripheral edema  
 Elevated JVP 
SIGNS OF DECOMPENSATION: 
 Icterus 
 Ascites 
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 Ecchymosis  
 Asterixis 
 Encephalopathy 
 Bleeding varices 
 Cruveilheir Baumgarten murmur 
 Fetor hepaticus 
 Caput medusae. 
COMPLICATIONS : 
 Portal hypertension 
 Spontaneous bacterial peritonitis 
 Hypersplenism  
 Variceal bleeding  
 Hepatorenal syndrome 
 Portopulmonary hypertension 
 Hepatic encephalopathy  
 Hepatopulmonary syndrome 
 Malignant transformation. 
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DIAGNOSIS: 
 Common laboratory investigations performed under the label LFT (liver 
function tests) are, 
1) Enzyme tests: 
 Serum aminotransferases (AST, ALT) 
 Serum alkaline phosphatase( ALP) 
 Gamma Glutamyl Transferase. 
2) Serum bilirubin – Total , direct and indirect bilirubin. 
3) Assessment of hepatic synthetic function: 
 Serum albumin  
 Prothrombin time and INR ( for coagulation factors) 
Aminotransferases: 
Both aspartate transaminase and alanine transaminase may be elevated 
upto 2 – 7 fold( < 400 IU/L ) , but can be normal in advanced stages of liver 
disease. AST/ALT ratio > 1 suggestive of alcoholic liver disease.  
Alkaline phosphatase: 
It is getting elevated in most forms of cirrhosis. But it will be less than 
three times the upper normal limit. High levels are noted in, 
22 
 
1) Primary biliary cirrhosis 
2) Primary sclerosing cholangitis 
Gamma Glutamyl Transferase: 
 It is  not a specific marker for alcoholic liver disease  
 It is  an easily inducible enzyme. 
 Elevated in all forms of fatty liver. 
 Serum bilirubin: 
 May be markedly increased in alcoholic hepatitis despite modest 
elevations in alkaline phosphatase. 
 It may be normal in compensated state but elevated bilirubin indicates 
fairly advanced liver disease. 
In primary biliary cirrhosis elevated bilirubin indicates poor prognosis. 
Serum Albumin : 
Albumin is solely synthesized by the liver . 
          In hepatitis albumin level < 3g/dl should raise the possibility of chronic 
liver disease. Hypoalbuminemia is not a  specific marker  for liver diseases. It 
can also occurs in protein losing enteropathy, nephrotic syndrome, protein 
energy malnutrition. 
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Prothrombin time: 
It detects the abnormality in the coagulation pathway particularly extrinsic 
and common pathway.  
           It  increases as liver disease progresses since coagulation factors are 
produced in liver. 
Serum Globulin: 
Elevated levels of globulin are seen in cirrhosis as various antigens are 
shunted away from liver, reach systemic circulation and elicit immunological 
response. Increased levels of IgM are seen in primary biliary cirrhosis, increased 
IgA is seen in alcoholic liver disease. 
Serum Sodium: 
Hyponatremia in chronic liver disease patients indicates poor prognosis. 
           It  is due to high levels of ADH seen in cirrhotic patients and consequent 
dilutional hyponatremia. Only those who have serum  levels of sodium less than 
120-125 mmol/L needs water restriction(15). 
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Hematological investigations:  
Anemia: May be due to       
• Blood loss due to bleeding diathesis. 
• Folate deficiency 
• Direct toxicity of alcohol 
• Hemolysis 
• Anemia of chronic disease 
• Hypersplenism 
Thrombocytopenia: 
Due to portal hypertension and hypersplenism, . It may cause bleeding if 
associated with coagulopathy. 
 Leucopenia, Neutropenia: 
Due to hypersplenism and splenic margination of  white bloodcells. 
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INVESTIGATIONS TO DETERMINE THE ETIOLOGY OF CHRONIC 
LIVER DISEASE: 
Alcoholic liver disease (ALD) :  
History of alcohol abuse.  
AST/ALT ratio > 2 due to  alcohol induced deficiency of pyridoxal 
phosphate(16). 
Liver biopsy may show features typical of alcoholic hepatitis, Mallory’s 
hyaline bodies, liver cell necrosis and fibrosis. 
Chronic hepatitis C: 
Anti HCV antibody 
          Quantitative PCR for HCV RNA  
          Liver biopsy to establish the severity of liver disease, macrovesicular 
steatosis. 
Chronic hepatitis B: 
 HBsAg 
 HBeAg 
 Quantitative PCR for  HBV DNA. 
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NASH: 
Associated features of metabolic syndrome like hyperglycemia, 
hyperlipidemia. 
 Liver biopsy 
Primary biliary cirrhosis: 
 Elevated alkaline phosphatase 
               Anti-mitochondrial antibody directed against pyruvate dehydrogenase 
complex  is considered to be specific for primary biliary cirrhosis. 
Primary Sclerosing Cholangitis (PSC): 
 Associated with inflammatory bowel disease( IBD ). 
 Contrast cholangiography shows diffuse, focal strictures and 
dilatation of bile ducts giving it a typical beaded appearance. 
Autoimmune hepatitis: 
 Increased gamma globulin levels 
 Anti-LKM1 antibody 
 Anti-smooth muscle antibody (ASMA)  
 Anti-nuclear antibodies. 
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Hemochromatosis: 
 Fasting transferrin saturation-More than 50% in men and women. 
 Plasma ferritin 
 Genetic testing 
 Liver biopsy for measurement of  liver iron  ( microgram/ G) and 
hepatic iron index. 
 
 Wilson’s disease: 
 Kayer Fleisher rings on slit lamp examination. 
 Decreased serum ceruloplasmin. 
 24 hour urinary copper >100mg 
 Copper content >200mg/g of liver tissue in liver biopsy.  
 
Alpha 1 anti-trypsin deficiency: 
 Decreased serum alpha1 anti-trypsin levels. 
 Genetic testing 
 
Right sided heart failure: 
 Electrocardiogram 
 Echocardiogram. 
28 
 
Imaging methods :  
Ultrasound abdomen: 
Provide useful information regarding liver size, echo texture. Useful 
screening to identify development of HCC (hepatocellular carcinoma) in a 
patient with preexisting chronic liver disease.  
Doppler ultrasound: 
Provides information regarding the blood flow in portal vein and  hepatic 
veins. 
Assess size of portal vein, splenic vein. Identify presence of collaterals. 
Portal venous pressure can be measured. 
CT Abdomen with or without contrast:  
 To assess liver size, shape.  
 To identify liver nodule. 
 To detect HCC. 
 
 MRI Abdomen: 
 Most useful in the evaluation of intrahepatic and extrahepatic biliary 
tree. 
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 To detect malignancy. 
Fibro scan : 
It is a newer modality and gaining popularity nowadays. It is a 
noninvasive method to assess the stiffness of the liver and evaluate liver fibrosis 
and cirrhosis by using electromagnetic waves(17). 
Liver biopsy: 
It  has proven value in the following  situations. 
1. Hepatocellular disease of  uncertain cause. 
2. Prolonged hepatitis with the possibility of chronic active hepatitis. 
3. Unexplained hepatomegaly. 
4. Unexplained splenomegaly. 
5. Filling defects in the liver in imaging. 
6. Staging of lymphoma. 
7. Fever of unknown origin. 
 
 
 
30 
 
ASSESSMENT OF SEVERITY AND PROGNOSIS:  
Severity may be assessed by 
1) Child Pugh’s scoring system. 
2) MELD scoring system. 
3) Liver biopsy 
 
 CHILD PUGH’S SCORING SYSTEM: 
Clinical and Lab 
 
 
Points 
1 2 3 
Ascites None 
Slight  
 
Moderate 
 
Albumin (g/dl) >3.5 2.8-3.5 <2.8 
Bilirubin (mg/dl) <2 2-3 >3 
Encephalopathy None Grade 1 and 2 Grade 3 and 4 
PT/INR 
 
<1.7 1.7-2.3 >2.3 
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Class A: Score 5-6  
                Survival at one and two year  100% and 65% respectively. 
 Class B: Score 7-9  
                Survival at one and two year  80% and 60% respectively. 
 Class C: Score 10-15  
                Survival at one and two years 45% and 35% respectively. 
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MELD SCORING SYSTEM: 
MELD (model for end stage liver disease) was initially developed to 
assess short term prognosis in patients with chronic liver disease who undergo 
TIPS procedure(2,5) (Trans jugular intra-hepatic Porto systemic shunt). But its 
usefulness to assess the prognosis and severity of chronic liver disease has been 
well validated in several studies.It consists of three variables 
1) Serum bilirubin 
2) Serum creatinine 
3) Prothrombin time INR(International Normalized Ratio). 
SCORE THREE MONTH 
MORTALITY (%) 
>40 71.3 
30-39 52.6 
20-29 19.6 
10-19 6 
<9 5 
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MANAGEMENT OF CHRONIC LIVER DISEASE 
MANAGEMENT IN A COMPENSATED STATE: 
 Adequate diet : 
 30-40 Kcal/kg body weight. 
 1.2-1.5 gram of protein per kg body weight per day(18). 
 Abstinence from alcohol.  
 Weight loss if obese. 
 Early detection and treatment of complications.  
 
Treatment of specific cause: 
 Antiviral therapy for chronic hepatitis B and C 
 Steroids and immunosuppressants for autoimmune hepatitis.                                                               
 Zinc, d-Penicillamine for Wilson’s disease.  
 Phlebotomy  for hemochromatosis. 
 Ursodeoxycholic acid for  primary biliary cirrhosis. 
 
DECOMPENSATED STATE: 
Treatment is aimed at Identification and treatment  of precipitating 
factors. Early detection and management of complications.  
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Hepatic encephalopathy : 
• Avoidance of precipitating factors. 
• Osmotic laxatives ( lactulose and lactitol ). 
• Rifaxamin 400mg three times a day.  
• Liver transplantation. 
 
Portal hypertension: 
• Propranolol 40-80 mg two times a day. Ascites and peripheral Ascites : 
• Sodium restriction <2 g per day. 
• Fluid restriction if there is Hyponatremia (< 120-125 mmol/L ). 
• Spironolactone starting dose 100 mg , maxi. dose 400mg per day 
• Furosemide 40 mg per day, maximum 160 mg per day 
• Large volume paracentesis with intravenous  albumin. 
 
Hepatorenal syndrome: 
• Avoidance of nephrotoxins 
• Intravenous albumin +  Midodrine 
• Octreotide                          
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Spontaneous bacterial peritonitis 
Cefotaxime 2 g IV tds or Ceftriaxone 1g iv BD for 7 days. 
          Norfloxacin 400 mg twice daily for 7 days. 
The patient should be maintained on lifelong prophylaxis with 
Norfloxacin 400mg OD . 
 
ROLE OF LIVER TRANSPLANTATION: 
Liver transplantation is considered when liver no longer has its ability to 
do its various functions. The following are the most common indication for liver 
transplantation. 
• Hepatitis C, B  
• Alcoholic liver disease 
• Autoimmune liver disease  
• Primary biliary cirrhosis. 
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MALIGNANCY INDUCED ASCITES: 
Malignant induced ascites is a marker of peritoneal carcinomatosis. The 
common etiologies for malignant induced ascites are carcinoma stomach, ovary, 
colorectum, lung, breast, pancreas, uterus, lymphoma. Malignant ascites 
accounts for 10% of the causes of ascites. The development of ascites is a worst 
prognostic sign in peritoneal carcinomatosis. The average life expectancy is 
approximately 20-24 weeks after the diagnosis of malignant ascites(18). 
 
The formation of malignant ascites is multifactorial. The pathogenesis of 
malignant ascites is multifactorial. It is postulated that ascites formation is 
related to a combination of increased vascular permeability and impaired 
lymphatic drainage by the tumour burden. There are five microscopic barriers 
exists in the peritoneum. They  prevents the  shift of proteins away from the 
intravascular space. They are as follows:  
 1. Capillary endothelium, 
 2. Capillary basement membrane,  
 3. Interstitium, 
 4. Mesothelial basement membrane, 
 5. Mesothelial lining cells(19). 
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With the combination of tight junctions and anionic macromolecules, an 
effective barrier is maintained in the peritoneum. It prevents the leakage of 
protein molecules into the peritoneal cavity. In 1922, Putnam described the 
peritoneal membrane as a “living membrane”. He demonstrated that crystalloid 
solutions when they are instilled into the peritoneal cavity, they gets equilibrated 
between the peritoneal cavity and the serum. The movement of colloid was  
described as transmission in one direction into the serum from the peritoneal 
cavity,with the help of some “vital (membrane) activity”, probably by 
phagocytosis or mechanical filtration through intercellular spaces. The relative 
impermeability of the capillary membrane to plasma proteins forms the basic 
mechanism  for osmotic gradients. It was initially described by Starling when he 
described about capillary forces. The starlings theory states that the exchange of 
fluid between the plasma and interstitium is dependingupon the hydrostatic and 
oncotic pressure in each compartment. Oncotic pressure differences forms the 
basis for fluid reabsorption from the interstitial space. It  prevents  edema 
formation(20) and it is mainly contributed by plasma proteins. 
The  macromolecules, proteins and cells do not preferentially leave the 
intravascular space. But they can accumulate in the peritoneal cavity and  return 
to the systemic circulation with the help  of the peritoneal lymphatic system. 
Recklinghausen is the one who first described the lymphatic stomata in the 
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body. He described that as small openings of lymphatics that connect the body 
cavity and lymphatic lumen which are responsible for movement of large 
particles into the vascular space. Several studies had  demonstrated that there are 
three lymphatic pathways in the abdomen by using India ink injection and 
transmission electron microscopy. The principal pathway begins with the 
lymphatic stomata. It enters the peritoneal lymphatics via networks in the 
diaphragm and then undergoing filtration through regional lymph nodes of the 
diaphragm, and finally  emptying into the thoracic duct(22). These different  
mechanisms of oncotic gradients and lymphatic drainage allows for a dynamic 
fluid balance created between the peritoneal cavity and the intravascular space. 
 
During  1953, Holm-Nielson demonstrated another important mechanism 
in the malignant ascites. India ink was injected into the peritoneal cavity in 
malignant ascites. It was  remained in the peritoneal cavity. It is  suggesting that  
lymphatic obstruction plays a  major role in pathogenesis of malignant ascites. 
Another scientist called Feldman later showed that in mice inoculated with 
tumor cells, radioactive labeled erythrocytes injected into the intra-peritoneal 
space failed to return to the intravascular space. It was  due to tumor infiltrating 
the lymphatics. It is further confirmed by histological evaluation, and 
subsequent to these events was the formation of ascites. It  was showed that 
39 
 
Radio-labeled red blood cells did not enter the intraperitoneal space at any 
increased rates until tumor burden had increased by 10 fold atleast. 
Development of ascites will not occur until late stages of tumor growth . The 
above mentioned  studies demonstrated the vital role  of lymphatic obstruction 
in the development of tumor related ascites. Several authors have offered 
theories regarding tumor metastasis. But  it is still not clear why cancer cells 
preferentially localizes to the peritoneal cavity rather than other sites and cause 
malignant ascites(24) . 
 
The mechanisms of ascitic fluid accummulation  appears to be the 
combination of increased vascular permeability and impaired lymphatic 
drainage. Recent studies shows that  vasculoendothelial growth factor (VEGF) 
appears to play an important role in increasing the vascular permeability. 
Tumour necrosis factor ( TNF ) also contributes to splanchnic hyperemia. So the 
cytokines which are released by the tumour cells plays an important role in the 
formation of malignant ascites.  
 
In >50% of cases of peritoneal carcinomatosis, ascites is the first detected 
sign of intra-abdominal malignancy. The causes of intra-abdominal fluid 
production are many, including both benign and malignant causes like cirrhosis, 
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congestive heart failure, nephrosis, pancreatitis, peritonitis, primary malignancy 
or hepatic metastases. It is improbable  to distinguish between benign ascites 
from malignant ascites by physical examination or radiographic techniques 
alone. So  Invasive testing becomes necessary to differentiate the two types. 
Abdominal paracentesis with ascitic fluid analyses can diagnose malignant 
causes of ascites production in most cases, but laparoscopic tissue sampling may 
be necessary in some cases. Ascitic fluid analysis consists of microscopic, bio 
chemical and cytological evaluation to  differentiate between infectious, 
inflammatory and malignancy induced ascites formation. In patients with 
peritoneal carcinomatosis, the ascites fluid has positive cytology, elevated 
protein concentrations and a low serum-ascites albumin gradient. While in some 
reports cytology is diagnostic in only 50%-60% of cases of malignant ascites, it 
has been demonstrated that up to 97% of patients with peritoneal carcinomatosis 
have positive cytology, indicating that the tumor is shedding cells into the 
peritoneal cavity, making it a highly sensitive test and the gold standard for 
diagnosing peritoneal carcinomatosis.  
 
Before concluding that cytology is negative for malignant cells we should 
repeat it thrice with adequate amount of sample after centrifuging the sample. 
The sample should be analysed immediately after processing it.   In patients with 
41 
 
peritoneal carcinomatosis and hepatic metastases, fluid cytology is positive and 
ascites protein concentrations are variable, but the serum-ascites albumin 
gradient remains elevated, with the addition of a markedly elevated serum 
alkaline phosphatase level (> 350 mg/dL). The usage  of tumor markers, 
especially CEA, CA-125 and α fetoprotein, are not reliable in diagnosing 
malignancy but they can be of help in identifying the primary tumor causing 
malignant ascites(27).  
 
The biochemical properties of ascites fluid, including fibronectin, 
cholesterol, lactate dehydrogenase, sialic acid, telomerase activity and proteases, 
have been studied and, while clinically helpful, they have not yet been found to 
be reliable in differentiating between malignant and benign ascites and they are 
not useful in routine analysis of ascitic fluid. So the combination of Tumor and 
biochemical markers along with the morphological features of the cytological 
smear, immunohistochemical staining and clinical history are important in 
determining both the presence of malignancy related ascites and the primary 
sites of metastatic carcinomas.  
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The quality of the ascitic fluid is distinctive in malignant ascites. It will 
have high ascitic fluid protein concentration, low SAAG, positive cytology.  
 
If the diagnostic workup does not reveal the primary source of malignancy 
but confirms the presence of a malignancy, a search for the tumor of origin 
should be started. In male patients with positive cytology, whose diagnostic 
workup remains negative despite blood tests and radiological imaging, it may 
not be useful to pursue further investigations because knowing the tumor of 
origin may not affect management or outcome(29).  
 
However, in female patients, if the conventional methods are failed to 
demonstrate the tumor of origin, laparoscopy or laparotomy should be done for 
tissue diagnosis, because patients with an ovarian malignancy will be  
responsive to tumor debulking and chemotherapy and their survival outcomes 
are better after  treatment. 
 
There are many studies which are trying to differentiate benign ascites 
from malignant ascites in a simple yet useful manner.Our study aim is to find 
out whether measuring gallbladder wall thickness by ultrasonography 
differentiates between portal hypertension induced ascites and malignant ascites.  
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Ultrasonography has an accuracy of 93-95% in determination of 
gallbladder wall thickness if it is 1 mm. It is 100% sensitive when the thickness 
is > 1.5 mm. The normal gallbladder appears as a pencil thin line which is 
echogenic on ultrasonogram. The thickness of gallbladder depends on the degree 
of  distension and pseudo thickening occurs in the post prandial state. 
 
The gallbladder is a hollow pear shaped viscera with thin and regular 
walls. It is located in the gallbladder fossa between IV and V segments of the 
liver. This area is devoid of visceral peritoneum. The gallbladder is divided into 
infundibulum, body and fundus. Its walls comprised of four layers.  
 
The innermost layer is mucosa which is formed by simple columnar 
epithelium and by a basal lamina. The second layer is made up of irregular 
muscular tissue. The third layer is by loose connective tissue and the last layer is 
formed by serosa. The function of the gallbladder is to store the bile and presents 
a volume of 30-50 ml bile(31). 
The sonographic images provide a faithful representation of the 
gallbladder which can be correlated with its anatomical structure. By means of 
ultrasonography it is possible to identify three layers. The innermost layer that is 
mucosa represents the linear, echogenic layer with regular surface. The second 
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one corresponding to the muscular layer which is thin and slightly hypoechoic. 
The outermost layer is corresponding to serosa and it is echogenic, linear and 
regular.  
 
LEFT: USG of a normal gallbladder after an overnight fast shows the wall 
as a pencil-thin echogenic line (arrow).RIGHT: US in the postprandial state 
shows pseudothickening of the gallbladder. 
According to several authors, the upper limit of normality for gallbladder 
wall thickness is 3 mm. But in patients under inappropriate fasting ,the 
gallbladder wall thickness may exceed that limit due to gallbladder smooth 
muscle contraction. So 8 hours fasting before doing the ultrasound examination 
is recommended. Another cause of pseudo thickening is erroneous insonation by 
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the transducer. In this case, the performance of certain maneuvers such as 
changing the decubitus will be useful to correctly delineate the thickness of the 
gallbladder wall. Gallbladder thickening is classified as mild when it is 4-7 mm 
and marked when it is > 7 mm and also as focal or diffuse thickening(32). In 
cirrhosis patients the key sonographic finding is preservation of mucosal 
regularity and echogenicity. 
 
The wall thickening occurs at the expense of hypoechoic layer 
corresponding to edema of the muscular layer and of the connective tissue. 
There are multiple causes of gallbladder wall thickening. They are 
 
1. Acute cholecystitis. 
2. Chronic cholecystitis. 
3. Acalculous cholecystitis. 
4. Adenomyomatosis. 
5. Gallbladder malignancy. 
6. Congestive cardiac failure. 
7. Cirrhosis of the liver. 
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8. Hypoalbuminemia. 
9. Renal failure. 
10. Pancreatitis 
11. Sepsis. 
 
We analyse the diagnostic usefulness of gallbladder wall thickness to 
differentiate between cirrhotic ascites with  portal hypertension and malignant 
ascites. In this cross sectional study , we enrolled 30 patients of cirrhotic ascites 
and 30 patients with ascites due to known peritoneal carcinomatosis.  
 
The inclusion criteria for diagnosis of cirrhosis includes spleenomegaly, 
spider angioma, palmar erythema and based on laboratory evaluation and liver 
biopsy. The abnormal sonographic findings of spleenomegaly, collateral veins in 
liver and splenic hilum, ascites, heterogenic liver echoes and irregular liver 
border were all defined as cirrhosis. Exclusion criteria includes acute and 
chronic renal insufficiency, heart failure, acute hepatitis, cholecystitis, sepsis.  
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All patients were examined after 8 hours of fasting and only  those 
patients were included who had a fill gallbladder. Three measurements of 
gallbladder wall thickness were taken at each site and average measurement was 
used for analysis. A single operator performed all the ultrasound examinations 
both in cirrhotic patients and peritoneal carcinomatosis patients. Real time 
bidimensional and Doppler ultrasound examinations were performed by using 
3.5 MHz transducer.  
 
Gallbladder was examined by means of images obtained in both supine 
and left lateral decubitus positions in order to evaluate the wall thickness , 
longest axis, width & depth. Portal vein was studied in supine and suspended 
respiration. Gallbladder wall thickness was measured in the longitudinal scan 
with ultrasound beam orthogonally oriented at the level of gallbladder anterior 
wall. 
 
 Normal gallbladder wall should measure less than 3-4 mm. It is 
recommended that this measurement  should be taken through the anterior wall 
of the gallbladder. Because the posterior acoustic shadowing will often make the 
posterior measurements inaccurate. The thickness was measured by vertical 
beam to the gallbladder wall and was measured from serosa to mucosa(34). 
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In liver cirrhosis gallbladder wall thickening is commoly observed.  The 
thickening of gallbladder wall in cirrhosis is multifactorial. Portal hypertension 
leads to stasis of blood in the gallbladder veins and viscera. It leads to 
congestion and edema of the gallbladder wall , that is more in cirrhotics when 
comparing to non-cirrhotics.  
 
The decreased intravascular osmotic pressure , hypoalbuminemia, 
decreased systemic vascular resistance are all contributing to the development of 
gallbladder wall thickening in cirrhosis patients. Diffuse gallbladder wall 
thickening is a non specific finding caused by several disorders. It includes both 
intrinsic ( acute cholecystitis, adenomyomatosis, gallbladder malignancy) and 
extrinsic causes such as acute hepatititis, cirrhosis of liver, congestive cardiac 
failure, AIDS, hypoalbuminemia, pancreatitis(36). 
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.  
Fig : USG Abdomen  in a 56 yr old male with cirrhosis depicts 
gallbladder wall thickening (arrow), surrounded by ascites. Note the irregular 
cirrhotic liver parenchyma. 
 
Gallbladder wall thickening is commonly reported in cirrhosis patients. It 
is often reported in association with portal hypertension. In a  model of  hamster 
cirrhosis , portal hypertension was associated with submucosal edema of the 
gallbladder and dilated vessels seen over the gallbladder wall. These histologic 
changes were related to gallbladder wall thickening which occurs in cirrhosis 
with portal hypertension. It is also associated with impaired contractility of the 
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gallbladder. It is well known that portal hypertension plays a crucial role in the 
transition of preclinical to clinical phase of cirrhosis of the liver. Portal 
hypertension also contributes to the development of hepatic encephalopathy, 
ascites.  
 
It also directly causes the emergence of collateral circulation and variceal 
hemorrhage.  Portal pressure can be measured   by invasive methods and the 
calculation  of hepatic venous pressure gradient ( HVPP ), with catheterisation 
of hepatic vein via the femoral or jugular route is most commonly used.   
 
Several studies have reported that hypoalbuminemia is a major 
determining factor in the development of gallbladder wall  thickening, where as  
other studies did not demonstrate such a correlation. Hypoalbuminemia causes 
edema and structural changes in the gallbladder wall.  It leads to gallbladder 
wall  thickening and also affect the gallbladder contractility. So the mechanisms 
which are responsible for gallbladder wall thickening seem to occur earlier and 
active in early stages of cirrhosis and precede the onset of portal 
hypertension(37).  
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In peritoneal carcinomatosis there is edema and inflammation of the 
peritoneum. This finding can be used a diagnostic sign for determining the 
etiology of the ascites in a case.  
 
 
Fig: Abdominal ultrasonogram revealed (arrow) thin gall bladder wall (2 mm in 
a patients with malignant ascites (stellate) due to ovarian carcinoma. 
 
 
 
  
 
 
MATERIALS AND METHODS 
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MATERIALS AND METHODS 
 
 
SETTING: 
 
 
 
This study was conducted at the Institute of Internal Medicine, Rajiv 
Gandhi Government General Hospital, and Madras Medical College. 
 
 
ETHICAL COMMITTEE APPROVAL: 
  
  
  
Obtained. 
 
 
 
STUDY DURATION: 
 
 
 
This study was conducted over a period of six months. 
 
 
 
STUDY POPULATION: 
 
 
 
Patients admitted with chronic liver disease with ascites, malignant 
induced  ascites at medical wards, Institute of Internal medicine. 
 
 
 
SAMPLE SIZE: 
 
Sixty patients. 
 
 
 
TYPE OF STUDY 
 
 
 
Cross sectional study. 
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INCLUSION CRITERIA: 
 
• Known case of cirrhosis with ascites. 
 
 
• Newly detected case of cirrhosis with ascites. 
 
 
• Known case of peritoneal carcinomatosis with ascites. 
 
 
             EXCLUSION CRITERIA: 
 
 
• Heart failure. 
 
 
• Acute kidney injury. 
 
• Chronic kidney disease. 
 
• Acute cholecystitis. 
 
• Acute hepatitis. 
 
• Sepsis. 
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DATA COLLECTION AND METHODS 
 
Informed consent will be obtained from each patient. 
 
Patients have their history taken according to a Questionnaire and subjected 
to clinical examination. 
 
Patients are subjected to routine blood investigations like complete 
blood count, renal function tests, liver function tests, PT-INR. 
 
Chest X-ray, Echo cardiography and US Gabdomen will be done. 
 
          Patients Gallbladder wall thickness will be assessed by 
Ultrasonography after 8 hours of fasting with fill gallbladder. Three 
measurements of gallbladder wall thickness were taken at each site and 
average measurement was used for analysis. 
 
  A single operator performed all the ultrasound examinations both in 
cirrhotic patients and peritoneal carcinomatosis patients. Real time 
bidimensional and Doppler ultrasound examinations were performed by using 
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3.5 MHz transducer. Gallbladder was examined by means of images obtained 
in both supine and left lateral decubitus positions in order to evaluate the wall 
thickness. Thickness more than 3 mm was considered significant. 
 
All the data will be entered in proforma (enclosed). 
 
Data will be analyzed using SPSS package and ANOVA. 
  
 
 
 
 
OBSERVATION  
&  
RESULTS 


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OBSERVATION AND RESULTS 
 
 
 
AGE VARIATION AMONG THE STUDY GROUPS: 
 
 
Group 
 
N 
 
Mean 
 
Std. Deviation 
 
P value 
 
 
Cirrhosis 30 51.03 10.08 
0.58 
Not significant 
 
Malignant 
30 53.47 11.057 
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SEX DISTRIBUTION: 
 
 
 
 
 
 
 
Sex 
 
 
 
Group 
 
Total 
 
 
P value  
 
 
Cirrhosis 
 
Malignant 
 
 
Males Count 22 19 41  
 
 
 
 
0.405 
 
 
NOT 
SIGNIFICANT 
 
 
 % within 
Sex 53.7% 46.3% 100.0% 
 % within 
Group 73.3% 63.3% 68.3% 
Females Count 8 11 19 
 % within 
Sex 42.1% 57.9% 100.0% 
 % within 
Group 26.7% 36.7% 31.7% 
Total Count 30 30 60 
 % within 
Sex 50.0% 50.0% 100.0% 
 % within 
Group 100.0% 100.0% 100.0% 
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SEX DISTRIBUTION 
 
 
 
 
 
Sex
FemaleMale
Co
u
n
t
30
20
10
0
Group
Cirrhosis
Malignant
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THICKENED GALLBLADDER IN CIRRHOSIS GROUP: 
 
 
 
CIRRHOSIS 
 
 
Gallbladder wall 
thickness in mm 
P value 
SERUM 
ALBUMIN (g/dl) 
Thickened 
gallbladder Normal 
Hypoalbuminemia Count 28 0 
<0.001 
 
SIGNIFICANT 
 %within serum 
albumin (g/dl) 
100% 0% 
 %within gall 
bladder wall 
thickness (mm) 
100% 0% 
Normal Count 0 2 
 %within serum 
albumin (g/dl) 
0% 100% 
 %within gall 
bladder wall 
thickness (mm) 
0% 100% 
 
Total 
 
  
28 
 
2 
 
 
 
 
 
  
60 
 
THICKENED GALLBLADDER IN MALIGNANT ASCITES GROUP: 
 
 
 
MALIGNANT 
ASCITES 
 
 
Gallbladder wall 
thickness in mm 
P value 
 
SERUM 
ALBUMIN (g/dl) 
Thickened 
gallbladder Normal 
Hypoalbuminemia  Count  3 16  
 
 
 
<0.603 
 
NOT 
SIGNIFICANT 
 %within serum 
albumin (g/dl) 
15.8% 84.2% 
 %within gall bladder 
wall thickness (mm) 
75% 61.5% 
Normal  Count 1 10 
 %within serum 
albumin (g/dl) 
9.1% 90.9% 
 %within gall bladder 
wall thickness (mm) 
25% 38.5% 
 
Total  
 
  
4 
 
26 
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THICKENED GALLBLADDER IN CIRRHOSIS GROUP: 
 
 
THICKENED GALLBLADDER IN CIRRHOSIS GROUP: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Serum Albumin (g/dL)
NormalHypoalbuminemia
Count
30
20
10
0
Thickened Gallbladder
Norma
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THICKENED GALLBLADDER IN MALIGNANT ASCITES GROUP 
THICKENED GALLBLADDER IN MALIGNANT ASCITES GROUP: 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Serum Albumin (g/dL)
NormalHypoalbuminemia
Count
20
10
0
Thickened Gallbladder
Normal
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CORRELATION BETWEEN SERUM ALBUMIN AND GALLBLADDER 
WALL THICKNESS: 
 
  
Group 
P value Cirrhosis Malignant 
Serum 
Albumin 
(g/dL) 
Hypoalbuminemia 
Count 28 19 
<0.001 
SIGNIFICANT 
% within 
Serum 
Albumin 
(g/dL) 
59.6% 40.4% 
% within 
Group 93.3% 63.3% 
Normal 
Count 2 11 
% within 
Serum 
Albumin 
(g/dL) 
15.4% 84.6% 
% within 
Group 6.7% 36.7% 
 
Total 
 
Count 
 
30 30 
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CORRELATION BETWEEN SERUM ALBUMIN AND GALLBLADDER 
 
WALL  THICKNESS: 
 
 
 
 
 
 
 
Serum Albumin (g/dL)
NormalHypoalbuminemia
Co
u
n
t
30
20
10
0
Group
Cirrhosis
Malignant
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THICKENED GALLBLADDER IN CIRRHOSIS AND PERITONEAL 
CARCINOMATOSIS: 
 
  
Group 
Cirrhosis Malignant 
Gall Bladder 
Wall Thickness 
in mm 
Thickened 
Gallbladder 
Count 28 4 
% within Gall 
Bladder Wall 
Thickness in 
mm 
87.5% 12.5% 
% within Group 93.3% 13.3% 
Normal 
Count 2 26 
% within Gall 
Bladder Wall 
Thickness in 
mm 
7.1% 92.9% 
% within Group 6.7% 86.7% 
Total 
Count 30 30 
% within Gall 
Bladder Wall 
Thickness in 
mm 
50.0% 50.0% 
% within Group 100.0% 100.0% 
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THICKENED GALLBLADDER IN CIRRHOSIS AND PERITONEAL 
CARCINOMATOSIS: 
 
 
 
 
 
Gall Bladder Wall Thickness in mm
NormalThickened Gallbladde
Co
u
n
t
30
20
10
0
Group
Cirrhosis
Malignant
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FREQUENCY OF PRIMARY MALIGNANCY AMONG THE PERITONEAL 
 
CARCINOMATOSIS GROUP: 
 
 
 
 Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid 
 30 50.0 50.0 50.0 
BREAST 2 3.3 3.3 53.3 
COLON 4 6.7 6.7 60.0 
OESOPHAGUS 2 3.3 3.3 63.3 
HCC 1 1.7 1.7 65.0 
KIDNEY 1 1.7 1.7 66.7 
LUNG 5 8.3 8.3 75.0 
LYMPHOMA 2 3.3 3.3 78.3 
OVARY 4 6.7 6.7 85.0 
PANCREAS 1 1.7 1.7 86.7 
PROSTATE 1 1.7 1.7 88.3 
STOMACH 7 11.7 11.7 100.0 
Total 60 100.0 100.0  
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RESULTS : 
 
AGE DISTRIBUTION : 
 
In our study among the cirrhosis group, 25% were in the age group of  
30- 40years, 52% were in the age group of 41-50 years, 23% were in the age group of 
51-60 years. The mean age is 51.03 yrs. Among the malignant induced ascites group, 
8% were in the 30-40yrs, 12% were in the age group of 40-50 yrs, 55% were in 51-60 
yrs, 25% were in the range of  61-70 yrs.  The mean age in this group is 53.43 yrs. 
 
 
SEX DISTRIBUTION: 
 
In our study among the cirrhosis group, 73% were males and 27% were 
females. Among the malignant induced ascites group 63% were males and 37%  were 
females. The correlation between sex distribution and gallbladder wall thickness was 
not significant. 
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THICKENED GALLBLADDER IN BOTH GROUPS: 
 
Among the cirrhosis group, 28 patients had thickened gallbladder ( >3 mm ) and 
2 patients had normal gallbladder wall thickness ( <3 mm ).  
 
           Among the malignant induced ascites group 26 patients had normal gallbladder 
wall thickness and 4 patients had thickened gallbladder. 
 
The correlation of gallbladder wall thickness between these two groups is 
highly significant ( p < 0.001 ).  
 
 
CORRELATION BETWEEN SERUM ALBUMIN AND GALLBLADDER 
WALL THICKNESS: 
 
Among  the cirrhosis group, 28 patients had hypoalbuminemia (< 3.5 g/ dl) 
which were forming 93.3% of the group. 2 patients had normal albumin levels  
(3.5-5 g/dl ) which formed 6.7% of the group. 
 
Among the malignant induced ascites group 19 patients had hypoalbuminemia 
which were forming 63.3 %  of the group. 11 patients had normal albumin levels 
which were forming 36.7 % of the group. 
 
 
           The correlation between hypoalbuminemia and thickening of gallbladder wall  
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is highly significant ( < 0.001 ).  
 
PRIMARY MALIGNANCY AMONG THE PERITONEAL 
CARCINOMATOSIS GROUP : 
 
Among this group, the minimum and maximum age of patients with peritoneal 
carcinomatosis was 32 and 70 respectively. Peritoneal carcinomatosis was mostly in 
males, 19 patients (63%). The minimum and maximum gallbladder wall thickness was 
1.3 mm and 3.70 mm respectively.   
 
The most common etiology was  cancer stomach (23%) followed by lung cancer 
(17%). Other common primary malignancies are ovarian and colon carcinomas, of 
each contributes about 13 % of the cases. Hepatocellular carcinoma, prostate, kidney , 
pancreatic malignancies were least common tumours in our study. 
 
  
  
 
 
DISCUSSION 
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DISCUSSION  
In a study by Hyang YS et al, gallbladder wall thickness had been measured in 
31 peritoneal carcinomatosis patients and 49 cirrhotic ascites patients. There are  three 
gallbladder patterns were recognized.  
 
A – Single layered , non thickened wall. 
B – Single layered and thickened wall. 
C – Double layered and thickened wall. 
Pattern A was frequently observed in malignant ascites patients. 
Pattern B and C were very commonly detected in cirrhotic ascites.    
 
If ‘ non thickened gallbladder wall’ is used as a criteria for the prediction of 
malignant ascites , the sensitivity is 80.6% and specificity is 93.9%. Our study is also 
in agreement with this previous study as the gallbladder was frequently thickened in 
cirrhosis induced ascites patients. 
 
In a study by Wang et al, the mean age group of patients in cirrhosis induced 
ascites was 50-64 yrs. In our study the mean age group  46-52 yrs. Another study by 
Marti bonmarti et al , 54 patients with ascites were observed.They had found that 
gallbladder wall thickness was significantly increased in patients with liver cirrhosis. 
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But no correlation was found between serum albumin and gallbladder wall thickness 
which suggested that increased gallbladder wall thickness in a cirrhotic patient is 
mainly due to portal hypertension. In contrast to this study,  our study showed that  
hypoalbuminemia is strongly correlated with thickened gallbladder wall in cirrhosis 
patients . 
 
In a study by Georgiev P et al , 60 patients with cirrhosis and 39 patients with 
peritoneal carcinomatosis were compared for gallbladder wall thickness. Most of the 
cirrhotic patients have thickened gallbladder , often with three layered structure ( 7.7+ 
or – 3.4 mm). The gallbladders of peritoneal carcinomatosis patients were most often 
not thickened ( 2.5 + or – 1.6 mm ) . The difference between the two groups were 
statistically significant in this regard. Thickening of the gallbladder was found in both 
groups of patients with decreased serum albumin level.  
 
In  a study by Afshin mohammadi et al,  The minimum and maximum age of 
patients with peritoneal carcinomatosis was 25 and 80 respectively. The mean age was 
54.9±11 years. Peritoneal carcinomatosis was mostly in males, 55 patients (55%). The 
minimum and maximum gallbladder wall thickness was 1.3 mm and 3.71 mm 
respectively. And mean GBWT was 2.2±0.6 mm. The least common etiologies for 
peritoneal carcinomatosis were hepatocellular carcinoma, lymphoma, ovarian and 
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prostate cancer, all together being only 2% of the cases. The most common etiology 
was gastric cancer (21%) followed by colon cancer (15%). In our study, the minimum 
and maximum age of patients with peritoneal carcinomatosis was 32 and 70 
respectively. Peritoneal carcinomatosis was mostly in males, 19 patients (63%). The 
minimum and maximum gallbladder wall thickness was 1.3 mm and 3.70 mm 
respectively.  The most common etiology was  cancer stomach (23%) followed by 
lung cancer (17%). 
 
The ascites induced by portal hypertension in our study was 73% in male 
patients and 23% in female patients. This reinforces the fact that the higher risk of 
hepatitis and cirrhosis in males due to involvement in high risk activities such as 
alcohol abuse, abnormal sexual behaviours, iv drug abuse. 
 
In the peritoneal carcinomatosis group, 63% were males and 37 % were 
females. The absence of gender correlation is also in agreement with the previous 
studies.    
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CONCLUSION 
 
 
 
• According to our study,  the sonographic study of the gallbladder will 
be helpful as a simple and initial screening tool in differentiating 
between cirrhosis induced and peritoneal carcinomatosis induced 
ascites. 
 
• Hypoalbuminemia is correlated well with the development of thickened 
gallbladder in cirrhosis induced ascites. 
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. 
 
 
LIMITATIONS OF STUDY 
 
 
 
• One limitation of this study is low number of patients and the results 
should be confirmed in large number of patients. 
 
• This is a cross sectional study. Randomized controlled trials should be 
done to confirm our results. 
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ANNEXURE 

‘‘ DIFFERENTIATION OF BENIGN FROM MALIGNANT INDUCED 
ASCITES BY MEASURING GALLBLADDER WALL THICKNESS’’. 
 
PROFORMA: 
Name         :                                                                 Patient ID 
No: Age/Sex     : 
IP No          : 
 
Patientcharacteristics Drugs 
DurationofCLD  Antibiotics 
Smoking Frusemide 
Alcoholism Spironolactone 
 Propranolol 
 
 
CLINICALPARAMETERS 
Pulse  BloodPressure  
Pallor Ascites 
Icterus Dilatedveinsovertheabdomen 
Edema Splenomegaly 
Featuresofhypogonadism Hepaticflap 
 
 
Investigations: 
 
RFT LFT 
Glucose  mg/dl Totalbilirubin  mg/dl 
Urea  mg/dl Directbilirubin  mg/dl 
Creatinine  mg/dl SGOT  U/l 
Na+  mEq/l SGPT  U/l 
K+  mEq/l ALP  U/l 
HBsAg  Totalprotein  g/dl 
Anti-HCV  Albumin  g/dl 
 
ULTRASOUND ABDOMEN: 
• Gallbladder wall thickness. 
• Spleenomegaly. 
• Ascites. 
• Collateral veins in liver and spleenic hilum. 
• Heterogenic liver echoes. 
• Liver border irregularity. 
 
 
 
 
 
 
 
  
 PATIENTCONSENTFORM 
 
 
StudyDetail : Differentiation of Benign from Malignant 
induced  ascites by measuring Gallbladder wall 
thickness. 
 
 
StudyCentre 
 
: 
RajivGandhiGovernmentGeneralHospital, 
Chennai. 
 
Patient’sName 
 
: 
 
 
Patient’sAge 
 
: 
 
 
Identification 
 
 
 
: 
 
Patient may check () these boxes 
 
I confirm that I have understood the purpose of procedure for the 
above study. I have the opportunity to ask question and all my 
questions and doubts have been answered to my complete 
satisfaction.                                                                           
I understand that my participation in the study is voluntary and that I 
am free to withdraw at anytime without giving reason, without my 
legal Rights being affected.                                                                                   
 
I understand that sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory authorities 
will not need my permission to look at my health records, both in 
respect of current study and any further research that may be 
conducted in relation to it, even if I withdraw from the study I agree to 
this access.  
 However, I understand that my identity will not be revealed in 
any information released to third parties or published, unless as 
required under the law. I agree not to restrict the use of any data or 
results that arise from this study.                                                                                       
 
 
 
I agree to take part in the above study and to comply with the 
instructions given during the study and faithfully cooperate with the 
study team and to immediately inform the study staff if I suffer 
from any deterioration in my health or well being or any 
unexpected or 
unusual symptoms.                                                                                        
 
 
 
I here by consent to participate in this study.                                                 
 
I hereby give permission to undergo complete clinical examination 
and diagnostic tests including haematological, biochemical, 
radiological 
tests.                                                                                                              
 
 
 
Signature/thumb impression                              Signature of Investigator 
 
Patient’s Name and Address:                             Study Investigator’s Name: 
 
 
 
      Dr.S.MUTHUKANI 
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1 36 M NA 2.1 60000 46 48 4.5 
2 38 M NA 1.4 43000 62 64 4.7 
3 42 M NA 1.3 41000 40 84 5.2 
4 45 M NA 1.5 15000 41 97 5.6 
5 47 M NA 2.4 26000 72 43 4.8 
6 43 M NA 2.5 100000 74 24 4.6 
7 52 M NA 1.7 86000 102 43 5.3 
8 44 M NA 1.2 76000 108 64 5.4 
9 41 M NA 1.3 54000 137 78 5.6 
10 36 M NA 1.1 48000 32 28 6.1 
11 49 M NA 2.1 42000 28 27 6.3 
12 38 M NA 2.7 30000 40 16 7.2 
13 45 M NA 2.4 20000 18 19 4.7 
14 44 M NA 3.1 78000 30 28 4.9 
15 50 M NA 3 112000 28 42 6.5 
16 43 M NA 2.7 112000 28 42 6.5 
17 48 M NA 1.8 67000 41 26 5.3 
18 51 M NA 1.4 43000 38 28 4.8 
19 52 M NA 1.2 49000 39 27 4.6 
20 41 M NA 1.3 29000 22 20 4.4 
21 47 M NA 2.2 34000 24 40 6.8 
22 49 M NA 2.6 19000 26 21 7.4 
23 38 F NA 1.7 62000 28 26 7.3 
24 42 F NA 2.6 77000 18 24 6.5 
25 45 F NA 1.4 68000 43 26 5.2 
26 47 F NA 1.7 43000 28 42 5.4 
27 46 F NA 1.6 32000 40 44 5.8 
28 43 F NA 1.2 41000 33 38 5.2 
29 52 F NA 1.4 49000 46 42 4.6 
30 51 F NA 2.3 68000 48 52 7.1 
 
31 57 M STOMACH 3.8 NA NA NA 1.3 
32 40 M HCC 3.1 NA NA NA 1.5 
33 46 M STOMACH 2.7 NA NA NA 1.7 
34 64 M LUNG 3.2 NA NA NA 2 
35 62 M COLON 3.4 NA NA NA 1.8 
36 34 M LYMPHOMA 3.5 NA NA NA 1.6 
37 46 M LUNG 3.2 NA NA NA 1.5 
38 48 M ESOPHAGUS 3 NA NA NA 2.1 
39 52 M PROSTATE 2.5 NA NA NA 1.7 
40 61 M COLON 3.5 NA NA NA 1.6 
41 68 M STOMACH 3.7 NA NA NA 1.9 
42 70 M PANCREAS 3.1 NA NA NA 2.5 
43 32 M LYMPHOMA 3.6 NA NA NA 2.1 
44 64 M STOMACH 3.2 NA NA NA 1.8 
45 62 M COLON 3.3 NA NA NA 1.9 
46 49 M ESOPHAGUS 1.2 NA NA NA 3.1 
47 53 M LUNG 3.5 NA NA NA 2.6 
48 58 M COLON 3.6 NA NA NA 3.7 
49 51 M STOMACH 3 NA NA NA 1.8 
50 54 F STOMACH 1.4 NA NA NA 3.2 
51 65 F KIDNEY 3.2 NA NA NA 1.6 
52 48 F OVARY 3.6 NA NA NA 1.7 
53 47 F LUNG 1.5 NA NA NA 3.1 
54 56 F BREAST 3.8 NA NA NA 2.8 
55 54 F OVARY 3.9 NA NA NA 1.5 
56 49 F BREAST 4 NA NA NA 1.4 
57 47 F LUNG 3.2 NA NA NA 2.1 
58 52 F OVARY 3.6 NA NA NA 2.4 
59 62 F STOMACH 3.8 NA NA NA 1.8 
60 58 F OVARY 4.2 NA NA NA 1.7 
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